ACADIA Pharmaceuticals Inc (ACAD)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The provided data on days of sales outstanding (DSO) for ACADIA Pharmaceuticals Inc does not contain specific numerical values, as they are indicated as "— days" for each reporting period from March 31, 2020, to December 31, 2024.
Days of sales outstanding (DSO) is a financial ratio that measures the average number of days a company takes to collect revenue after a sale is made. A lower DSO value generally indicates that a company is collecting payments from customers more quickly, which can be a positive indicator of efficient accounts receivable management.
Without the specific DSO values for ACADIA Pharmaceuticals Inc, it is not possible to conduct a detailed analysis of its accounts receivable efficiency over time. It is important to track and analyze DSO trends over multiple periods to assess the company's ability to manage its receivables effectively and maintain a healthy cash flow position. A consistent or decreasing trend in DSO could suggest improved cash flow management, while an increasing trend may indicate potential issues with collecting payments from customers promptly.
Peer comparison
Dec 31, 2024